Research & Development



  天黑的時候小狗兒回來了,他已經非常的疲憊了,坐在火塘邊上喝了一口熱茶之後才算是精神了一些。   用指甲花染色時間很關鍵,沒有十二個時辰是沒有好效果的,迷迭尕說了,要是一次沒有染好,第二次就不靈光了。17彩票app下载   “算了吧,我不想吃蛋糕了,再說你沒有雞蛋!”997彩票app下载   阿嬌靠在一張軟榻上,背後就是道飛瀑,山風一吹涼氣襲人。   即便是在發射弩箭的功夫,小狗子依舊注意著周邊的狀況,很快,他就發現,跟他們做著同樣事情的人很多,遠比何愁有說的三十二個人多……9亿彩票app下载安装   甦稚的胸可沒有她的大,臀部也沒有宋喬的圓潤,對這一點宋喬還是非常自信的。

Our discovery and development platforms for drug and cell-based therapies allow us to both create and retain significant value within our therapeutic franchise areas of cancer and inflammatory diseases. Scientists and physicians at Celgene are the driving force behind our success, enabling target-to-therapeutic platforms that integrate both small-molecule and cell-based therapies.

Connect? Registries

The Connect??Registries are observational, hematologic patient registry studies in Multiple Myeloma (Connect?MM), Chronic Lymphocytic Leukemia (Connect?CLL) and Myelodysplastic Syndromes/Acute Myeloid Leukemia (Connect?MDS/AML) and are sponsored by Celgene Corporation. These studies are designed to observe the routine care of patients through the course of their disease. Unlike clinical trials, registries do not require or provide any specific medications or healthcare services, but leave those decisions to the treating doctors and their patients.
Connect? Registries logo